Lifetime cannabis use and childhood trauma increase risk of psychosis in carriers of CNR1 genetic variants: findings from the STREAM study

Imagem de Miniatura
Arquivos
art_LOUREIRO_Lifetime_cannabis_use_and_childhood_trauma_increase_risk_2023.PDF (342.81 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC BRASILEIRA PSIQUIATRIA
Autores
LOUREIRO, Camila Marcelino
CORSI-ZUELLI, Fabiana
FACHIM, Helene Aparecida
SHUHAMA, Rosana
OLIVEIRA, Adrielle Martins de
DALTON, Caroline F.
LOUZADA-JUNIOR, Paulo
BELANGERO, Sintia Iole
COELI-LACCHINI, Fernanda
Citação
BRAZILIAN JOURNAL OF PSYCHIATRY, v.45, n.3, p.226-235, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objectives: Gene-environment interactions increase the risk of psychosis. The objective of this study was to investigate gene-gene and gene-environment interactions in psychosis, including single nucleotide variants (SNVs) of dopamine-2 receptor (D2R), N-methyl-d-aspartate receptor (NMDAR), and cannabinoid receptor type 1 (CB1R), lifetime cannabis use, and childhood trauma.Methods: Twenty-three SNVs of genes encoding D2R (DRD2: rs1799978, rs7131056, rs6275), NMDAR (GRIN1: rs4880213, rs11146020; GRIN2A: rs1420040, rs11866328; GRIN2B: rs890, rs2098469, rs7298664), and CB1R (CNR1: rs806380, rs806379, rs1049353, rs6454674, rs1535255, rs2023239, rs12720071, rs6928499, rs806374, rs7766029, rs806378, rs10485170, rs9450898) were genotyped in 143 first-episode psychosis patients (FEPp) and 286 communitybased controls by Illumina HumanCoreExome-24 BeadChip. Gene-gene and gene-environment associations were assessed using nonparametric Multifactor Dimensionality Reduction software.Results: Single-locus analyses among the 23 SNVs for psychosis and gene-gene interactions were not significant (p 4 0.05 for all comparisons); however, both environmental risk factors showed an association with psychosis (p < 0.001). Moreover, gene-environment interactions were significant for an SNV in CNR1 and cannabis use. The best-performing model was the combination of CNR1 rs12720071 and lifetime cannabis use (p < 0.001), suggesting an increased risk of psychosis.Conclusion: Our study supports the hypothesis of gene-environment interactions for psychosis involving T-allele carriers of CNR1 SNVs, childhood trauma, and cannabis use.
Palavras-chave
Cannabis use, childhood trauma, first-episode psychosis, single nucleotide variants
URI
https://observatorio.fm.usp.br/handle/OPI/56156
Referências
  1. AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x
  2. Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
  3. Bernstein DP, 2003, CHILD ABUSE NEGLECT, V27, P169, DOI 10.1016/S0145-2134(02)00541-0
  4. Crippa JAS, 2001, ACTA PSYCHIAT SCAND, V103, P465, DOI 10.1034/j.1600-0447.2001.00185.x
  5. Del-Ben CM, 2019, BRIT J PSYCHIAT, V215, P726, DOI 10.1192/bjp.2019.110
  6. Del-Ben Cristina Marta, 2001, Revista Brasileira de Psiquiatria, V23, P156, DOI 10.1590/S1516-44462001000300008
  7. Di Forti M, 2019, LANCET PSYCHIAT, V6, P427, DOI 10.1016/S2215-0366(19)30048-3
  8. Di Forti M, 2009, BRIT J PSYCHIAT, V195, P488, DOI 10.1192/bjp.bp.109.064220
  9. Ferretjans R, 2022, BRAZ J PSYCHIAT, V44, P26, DOI 10.1590/1516-4446-2020-1650
  10. First M., 1997, STRUCTURED CLIN INTE
  11. Garani R, 2021, PROG NEURO-PSYCHOPH, V106, DOI 10.1016/j.pnpbp.2020.110096
  12. Gayer-Anderson C, 2020, SOC PSYCH PSYCH EPID, V55, P645, DOI 10.1007/s00127-020-01831-x
  13. Gilbert-Diamond Diane, 2011, Curr Protoc Hum Genet, VChapter 1, DOI 10.1002/0471142905.hg0114s70
  14. González-Mariscal I, 2016, SCI REP-UK, V6, DOI 10.1038/srep33302
  15. Gouvêa ES, 2017, REV BRAS PSIQUIATR, V39, P160, DOI 10.1590/1516-4446-2016-1969
  16. Grassi-Oliveira R, 2006, REV SAUDE PUBL, V40, P249, DOI 10.1590/S0034-89102006000200010
  17. Guloksuz S, 2019, WORLD PSYCHIATRY, V18, P173, DOI 10.1002/wps.20629
  18. Guo ZM, 2016, NEUROSCI LETT, V630, P132, DOI 10.1016/j.neulet.2016.07.038
  19. Hahn LW, 2003, BIOINFORMATICS, V19, P376, DOI 10.1093/bioinformatics/btf869
  20. He M, 2019, INT J CLIN EXP PATHO, V12, P628
  21. Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362
  22. Ho BC, 2011, SCHIZOPHR RES, V128, P66, DOI 10.1016/j.schres.2011.02.021
  23. Huo YX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08666-4
  24. Jongsma HE, 2018, JAMA PSYCHIAT, V75, P36, DOI 10.1001/jamapsychiatry.2017.3554
  25. Kuzman MR, 2019, EUR PSYCHIAT, V61, P88, DOI 10.1016/j.eurpsy.2019.07.004
  26. Laksmidewi AAAP, 2021, J NEURAL TRANSM, V128, P615, DOI 10.1007/s00702-021-02326-y
  27. Lee G, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00185
  28. Liang X, 2019, AGING-US, V11, P3704, DOI 10.18632/aging.102008
  29. Liu YP, 2019, BMC MED GENET, V20, DOI 10.1186/s12881-019-0757-3
  30. Loureiro CM, 2018, SCHIZOPHR RES, V202, P55, DOI 10.1016/j.schres.2018.06.037
  31. Mackie K, 2005, HANDB EXP PHARMACOL, V168, P299
  32. Martel JC, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01003
  33. McCutcheon RA, 2020, WORLD PSYCHIATRY, V19, P15, DOI 10.1002/wps.20693
  34. McCutcheon RA, 2020, JAMA PSYCHIAT, V77, P201, DOI 10.1001/jamapsychiatry.2019.3360
  35. Ménard C, 2002, NEURON, V36, P597, DOI 10.1016/S0896-6273(02)01026-7
  36. Moore JH, 2015, METHODS MOL BIOL, V1253, P301, DOI 10.1007/978-1-4939-2155-3_16
  37. Niu HM, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0398-5
  38. Nkam I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170147
  39. Oh S, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S9-S5
  40. Olney JW, 1999, J PSYCHIAT RES, V33, P523, DOI 10.1016/S0022-3956(99)00029-1
  41. Onaivi ES, 2009, INT REV NEUROBIOL, V88, P335, DOI 10.1016/S0074-7742(09)88012-4
  42. OVERALL JE, 1962, PSYCHOL REP, V10, P799
  43. Paoletti P, 2013, NAT REV NEUROSCI, V14, P383, DOI 10.1038/nrn3504
  44. Pasman JA, 2018, NAT NEUROSCI, V21, P1161, DOI 10.1038/s41593-018-0206-1
  45. Popovic D, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00274
  46. Prats C, 2017, EUR PSYCHIAT, V40, P60, DOI 10.1016/j.eurpsy.2016.07.006
  47. Pulido-Salgado M, 2015, PROG NEUROBIOL, V132, P1, DOI 10.1016/j.pneurobio.2015.06.003
  48. Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
  49. Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595
  50. Ritchie MD, 2003, GENET EPIDEMIOL, V24, P150, DOI 10.1002/gepi.10218
  51. Rodríguez-Muñoz M, 2016, ONCOTARGET, V7, P55840, DOI 10.18632/oncotarget.10095
  52. RStudio Team, RSTUDIO INT DEV R
  53. SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0
  54. Sánchez-Blázquez P, 2014, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00169
  55. Seifert J, 2007, NEUROSCI LETT, V426, P29, DOI 10.1016/j.neulet.2007.08.008
  56. Singh SP, 2005, SCHIZOPHR RES, V80, P117, DOI 10.1016/j.schres.2005.04.018
  57. Singh T, 2022, NATURE, V604, P509, DOI 10.1038/s41586-022-04556-w
  58. Stilo SA, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/s11920-019-1091-3
  59. Stringer S, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.36
  60. Trubetskoy V, 2022, NATURE, V604, P502, DOI 10.1038/s41586-022-04434-5
  61. Tsai SJ, 2000, PSYCHIATR GENET, V10, P149, DOI 10.1097/00041444-200010030-00008
  62. Wahbeh MH, 2021, GENES-BASEL, V12, DOI 10.3390/genes12121850
  63. Yang YF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125925
  64. Zhang JP, 2011, EXPERT OPIN DRUG MET, V7, P9, DOI 10.1517/17425255.2011.532787
  65. Zhang KR, 2009, J AFFECT DISORDERS, V114, P224, DOI 10.1016/j.jad.2008.07.012
  66. Zhang YX, 2015, SCI REP-UK, V5, DOI 10.1038/srep12984

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPR
Artigos e Materiais de Revistas Científicas - LIM/39